LMAT (LeMaitre Vascular) Short-Term Debt: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LMAT LeMaitre Vascular Inc LMAT
100 GF Score
Price $81.45
GF Value $95.26
Valuation Modestly Undervalued
View Full Analysis

What is LeMaitre Vascular Short-Term Debt?

LeMaitre Vascular LMAT +0.78% 100 Short-Term Debt is $0.0 Mil as of Jun. 2026. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued).

LeMaitre Vascular's Short-Term Debt for the quarter that ended in Jun. 2026 was $0.0 Mil.

LeMaitre Vascular Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

LeMaitre Vascular Short-Term Debt Related Terms

LeMaitre Vascular Short-Term Debt Historical Data

* Premium members only.

The historical data trend for LeMaitre Vascular's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LeMaitre Vascular Short-Term Debt Chart

LeMaitre Vascular Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LeMaitre Vascular Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LMAT
100GF Score
LeMaitre Vascular Inc LMAT
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.0 Mil mean?
LeMaitre Vascular (LMAT) has a Short-Term Debt of $0.0 Mil as of Jun. 2026.
Is LeMaitre Vascular's Short-Term Debt too high?
LeMaitre Vascular's current Short-Term Debt is $0.0 Mil. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Short-Term Debt compare to PLSE and XRAY?
LeMaitre Vascular's Short-Term Debt of $0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. LeMaitre Vascular's current Short-Term Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current Short-Term Debt is $0.0 Mil. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current Short-Term Debt is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LeMaitre Vascular (LMAT) Overvalued in 2026?

Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued. The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26. GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.

Key valuation signals for LMAT:

  • Short-Term Debt: $0.0 Mil
  • GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
  • GF Score™: 100/100

No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LeMaitre Vascular Business Description

Other Exchanges LHU:Germany
Address 63 Second Avenue, Burlington, MA, USA, 01803
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score

Get the complete analysis for LMAT

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.45
Price
$95.26
GF Value